MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/2767-9764.crc-25-0096

Медицинская библиотека · Cancer research communications · 2025

Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC Models.

Brim Benjamin C, Leon Andres F, Beatson Erica L, Kindrick Jessica D, Bhadresha Kinjal, Zhang Xiaohu, Napoli Giulia C, Risdon Emily N, Schmidt Keith T, Wilson Kelli M, McKnight Crystal, Beck Erin, Klumpp-Thomas Carleen, Ceribelli Michele, Yin JuanJuan, Sowalsky Adam G, Price Douglas K, Chau Cindy H, Thomas Craig J, Figg William D

СтатьяResearch Support, N.I.H., IntramuralПеревод в очереди

Аннотация

UNLABELLED: There is an unmet need to develop novel treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). Patients often develop resistance to next-generation hormonal therapies that target the androgen receptor (AR) axis (e.g., abiraterone and enzalutamide). A splice variant of AR, AR-V7, is associated with resistance to these inhibitors as well as mCRPC progression and poor prognoses. We embarked upon a high-throughput screen to identify synergistic combinations of targeted therapies using two CRPC cell lines, LNCaP95 and VCaP-CR. Combinations targeting BCL2L1 (Bcl-xL) (A-1331852 and navitoclax) and MCL1 (S63845) synergistically decreased cell viability and induced apoptotic activity via cleavage of PARP, caspase 3, and caspase 7 across AR-V7-expressing CRPC cell lines (LNCaP95, VCaP-CR, and 22Rv1) and a patient-derived organoid model (LuCaP 167CR). We also explored the use of a Bcl-xL-specific proteolysis-targeting chimera degrader (PROTAC) to minimize platelet toxicity associated with Bcl-xL inhibitors. We showed similar synergistic efficacy with the Bcl-xL-targeting PROTAC in combination with S63845 in the three-dimensional spheroid models. Our findings support further preclinical development of Bcl-xL and Mcl-1 inhibitors for mCRPC.

SIGNIFICANCE: Using an unbiased, combinatorial, high-throughput drug screen, we identified the combination of co-targeting Bcl-xL and Mcl-1 to be highly synergistic across AR-V7-expressing CRPC models. We showed efficacy in higher-order models through validation across in vitro models spanning two-dimensional cell culture, three-dimensional cell culture, and a patient-derived organoid model. These findings identify a promising therapeutic strategy for patients with AR-V7-expressing CRPC.

Для цитирования: Brim Benjamin C, Leon Andres F, Beatson Erica L, Kindrick Jessica D, Bhadresha Kinjal, Zhang Xiaohu, Napoli Giulia C, Risdon Emily N, Schmidt Keith T, Wilson Kelli M, McKnight Crystal, Beck Erin, Klumpp-Thomas Carleen, Ceribelli Michele, Yin JuanJuan, Sowalsky Adam G, Price Douglas K, Chau Cindy H, Thomas Craig J, Figg William D. Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC Models.. Cancer research communications. 2025. DOI: 10.1158/2767-9764.crc-25-0096.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.